Increased investment in radiotherapy can significantly improve cure rates for European cancer patients. In the UK and Netherlands, calls for increased funding led to substantial improvements. However, under- utilization of radiotherapy is common in many EU countries due to inadequate infrastructure and staffing.
A randomised clinical trial found that post-operative radiotherapy significantly improved biological and clinical progression-free survival in men with high-risk prostate cancer. The study showed a clear benefit in terms of biological progression-free survival for men who received radiotherapy treatment in addition to surgery.
A new radiotherapy regime has been shown to significantly reduce local disease recurrence rates in young women with breast cancer. The treatment involves adding a boost dose of radiation to the tumour bed, resulting in a 5-year local recurrence rate of 8.5% in women under 35 years old.
Experts call on EU politicians to improve cancer treatment access, modernize healthcare through increased funding and reduced bureaucracy. The European CanCer Organisation highlights the need for political will to translate scientific discovery into practical treatments.
A novel compound called ZK-CDK has been shown to inhibit both tumour cell growth and angiogenesis in human cancer cells. The compound was tested on mice models and found highly efficacious, particularly in slow-growing hormone-independent breast and prostate tumours.
Analysis of Croatian skeletal remains reveals only four cases of neoplastic disease, with all three conditions being benign. The study highlights the increasing incidence of cancer due to increased life expectancy and lifestyle factors.
Researchers developed a novel treatment combining chemotherapy, radiation therapy, and immunotherapy to target genetic mechanisms protecting metastatic tumor cells. The treatment successfully induced apoptosis in tumor cells by blocking oncogene expression and DNA synthesis.
The ECCO conference emphasized the need for risk-reducing interventions, genetic counseling, and psychological support for breast cancer patients. Delegates called for no upper age limit in treatment plans and patient participation in clinical trials based on performance status.
A new large-scale trial will test the efficacy of a genetically personalised treatment for breast cancer, using microarrays to identify specific molecular signatures. The MINDACT trial aims to spare patients at low risk of relapse from unnecessary chemotherapy, resulting in reduced side effects and healthcare costs.
A new study found a significant disparity in breast conservation rates between countries, with Poland having the lowest rate of only 2% and the USA the second-highest at 56%. The variation was attributed to factors such as tumour characteristics, access to radiotherapy, and screening programmes.
A Canadian study found that breast cancer patients who participated in clinical trials had a 60% lower risk of dying, compared to those who did not. Larger treatment centers also showed better survival rates, attributed to participation in research.
A South African doctor is criticizing the government's prioritization of arms deals over women's health, citing a lack of investment in breast cancer care. The doctor urges developed countries to apply political pressure to help build better breast cancer care in Africa.
A survey of Swedish breast cancer patients found that women prefer follow-up visits at breast centers rather than with their GP, but want more time for discussion. The study suggests that nurse-led follow-ups could increase patient satisfaction and reduce healthcare costs.
Recent breast cancer trials using aromatase inhibitors (AIs) reported results early due to significant advantages over tamoxifen. However, Dr. Martine Piccart argues that this can lead to unanswered questions about long-term efficacy and side effects. She proposes new guidelines for better data collection and risk-benefit analysis.
A new study found that women with ductal carcinoma in situ (DCIS) who undergo conservation treatment have a similar rate of survival compared to those who undergo mastectomy. Close monitoring and regular screenings are crucial for successful treatment and early detection of recurrence.
Breast cancer patients in Europe increasingly use complementary and alternative therapies (CAMs) to improve quality of life. CAMs may complement conventional treatments but can also interact dangerously with drug regimes, requiring careful consideration by doctors and patients.
Dr Yeo's study found that prophylactic lamivudine significantly reduces the incidence of HBV reactivation and hepatitis in breast cancer patients. The drug was effective in reducing the risk of liver damage caused by HBV reactivation during and after chemotherapy.
Dr. Berrino suggests that dietary factors play a major role in breast cancer prevention, particularly for women carrying BRCA mutations. By adopting a healthier diet, these women can reduce their risk of developing the disease.
Scientists have discovered that breast cancer metastases have a strikingly similar genetic profile to their primary tumours. This breakthrough discovery could enable doctors to choose the best treatment for each patient based on their unique tumour characteristics.
Dr. Eric Winer emphasizes the importance of rigorous testing for complementary and alternative therapies (CAMs) due to safety concerns and limited scientific evidence. Many CAMs have not undergone thorough evaluation, leading to potential interactions with standard treatments.
A recent study found that young breast cancer survivors experience more severe long-term after effects, including arm problems and fatigue. Women diagnosed over 50 years old tend to report fewer symptoms than younger women.
A new diagnostic tool, BCPC, uses microarray technology to analyze tumor genetic signatures and provide personalized treatment recommendations for breast cancer patients. The tool aims to improve patient outcomes by avoiding over-treatment and reducing costs of treatment.
In the phase III trial, exemestane demonstrated superior efficacy over tamoxifen in patients with hormone-responsive metastatic breast cancer, with a median progression-free survival of 10.9 months compared to 6.7 months for tamoxifen. The study also showed improved response rates and safety profile for exemestane.
Older women with breast cancer often lose out on effective treatments, with prognosis not linked to tumour factor. Health policymakers need to develop strategies for elderly patients, while doctors must find suitable treatments tailored to their needs.
Researchers found a 1.7-fold increase in cardiovascular death among breast cancer patients who received radiotherapy compared to those who didn't. However, the risk was lower for non-irradiated patients, suggesting that breast cancer may have a protective effect on cardiovascular disease.
A recent study has confirmed that women with BRCA breast cancer who undergo conservation surgery and radiotherapy have a lower risk of recurrence compared to those without genetic mutations. The only factor associated with a higher risk of recurrence is young age, according to the researchers.
The European Parliament and Commission are urging a unified EU approach to combat breast cancer, citing the potential for 90% of patients to be cured with early diagnosis. Breast cancer centers must meet specific requirements, including 150 operations per year and multidisciplinary case conferences.
A study found that a quarter of 50-69-year-old women had dense breast patterns more commonly associated with younger women. Breast cancer screening in postmenopausal women is effective, but cancers can still go undetected due to high mammographic density.
A randomised controlled trial of breast self-examination in nearly 100,000 Russian women found no reduction in deaths from breast cancer. Instead, women who performed regular self-examinations had more frequent consultations for benign breast lesions, leading to increased anxiety and unnecessary surgical biopsies.
The report analyzed data from 22 countries and 42 types of cancer, showing average five-year survival rates ranging from 94% for lip cancer to less than 4% for pancreatic cancer. Regional variations were found, with some Eastern European countries having lower survival rates and western Europe performing better.
A large-scale clinical study by Nordic collaboration has provided new insights into the effects of chemotherapy in colorectal cancer. The analysis demonstrated that among 2,223 patients, those given chemotherapy as part of routine care had a five-year survival rate of 56%, compared to 49% for those treated by surgery alone.
In Sweden, rectal cancer patients have seen a dramatic improvement in five-year survival rates, jumping from 50% to 60%, thanks to changes in hospital practice and quality assurance measures.
The EU's new clinical trial directive may hinder international collaborations, leading to delays in cancer treatment development. This could result in patients being deprived of life-saving treatments, as the effectiveness of new drugs would be determined solely by pharmaceutical industry-sponsored research.
A study of 5,016 children with cancer found that five-year survival rates increased from 23% in the 1960s to 70% in the 1990s. However, many survivors experience long-term side effects, such as reduced growth hormone production and cardiac problems.
A recent study found a statistically significant positive relationship between stress and breast cancer, independent of potential confounding factors. Women who experienced stress had double the risk of developing breast cancer over a 24-year period compared to those with no stress.
A study of 2,604 children with solid tumours found a significant link between mothers' breast cancer and their child's age at diagnosis. The risk is higher for younger children and boys, suggesting hormonal disruption during pregnancy may play a role.
A new study by ATAC found that Anastrozole enhances disease-free survival and reduces breast cancer recurrence, but increases bone fracture risk. The fracture rate peaks at 18-24 months before stabilizing, suggesting the overall benefit of Anastrozole remains
The European CanCer Organisation warns that the definition of a trial sponsor may lead to the collapse of independent clinical trials, particularly in children's cancers and rare adult cancers. Publicly funded clinical trials will be forced to stop due to financial and administrative burdens.
A 57-year study found that hereditary retinoblastoma patients have a significantly higher risk of developing a second primary cancer, with an increased incidence of melanomas and sarcomas. The risk is independent of radiotherapy treatment.
A Phase III trial found that docetaxel significantly improved survival rates and overall response rates compared to paclitaxel in women with advanced, incurable breast cancer. The median survival time was 15.4 months for docetaxel patients versus 12.7 months for paclitaxel patients.
Prostate cancer mortality rates are falling fast in the US and Europe due to earlier diagnosis and hormonal treatments. Research shows that prompt surgery and hormonal therapy can improve 10-year survival rates for both prostate and breast cancers.
A new trial found a significant survival benefit from adjuvant chemotherapy in non-small cell lung cancer, increasing patient lifespan by 4.1%. The study suggests that toxicity is still a major concern and calls for better tools to identify patients who will benefit from treatment.
The European Cancer Patient Coalition is hindered by language barriers, with fewer than 50% of Europeans speaking a second language, including English. Digital divide also persists, with varying internet access across countries, affecting the coalition's ability to operate effectively.
Researchers identify key genes involved in cancer development, including BRAF, and develop targeted drugs to combat the disease. A new approach to cancer treatment is being explored by targeting mutated genes, offering new hope for more efficient treatments.
A new coalition of cancer patients is working to promote better treatment, care, and research across Europe. The group hopes to influence European health policymaking and ensure access to high-quality screening, treatment, and care for all cancer patients.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
Researchers identified specific genetic variations linked to differences in normal tissue radiation damage, potentially allowing for personalized treatment approaches. The study's findings suggest that a person's genetic pattern can predict their tolerance to radiotherapy, enabling more effective treatment and reduced side effects.
Breast cancer patients participating in an online support group experienced improved well-being and empowerment through sharing personal experiences, asking for advice, and expressing emotions. The study highlights the importance of internet access for social support and low-income groups.
The study evaluated 27 surgeons in 23 centers and found that quality of surgery is independent of caseload. The parameters used included length of surgery, blood loss, postoperative continence, and PSA levels after surgery.
A new HPV vaccine targeting high-risk types could prevent up to 84% of cervical cancer cases. Testing a cocktail of these virus types could provide sufficient guidance for clinical decisions and future screening programmes.